Evidence map›Paper›PMID 37922311›Full record

ArticleCell reports2023

Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling.

Crissy Dudgeon, Anthony Casabianca, Chris Harris, Charline Ogier, Mélanie Bellina, Stephany Fiore, Agnes Bernet, Benjamin Ducarouge, David Goldschneider, Xiaoyang Su and 12 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Unveiling the cancer risk nexus of the steatotic liver.Trends in endocrinology and metabolism: TEM · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 2 countries.

Crissy DudgeonRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Anthony CasabiancaDepartment of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
Chris HarrisDepartment of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
Charline OgierDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Mélanie BellinaApoptosis, Cancer and Development Laboratory - Equipe labellisée "La Ligue," LabEx DEVweCAN, Institut Convergence PLAsCAN, Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France; Netris Pharma, 69008 Lyon, France.
Stephany FioreApoptosis, Cancer and Development Laboratory - Equipe labellisée "La Ligue," LabEx DEVweCAN, Institut Convergence PLAsCAN, Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France.
Agnes BernetApoptosis, Cancer and Development Laboratory - Equipe labellisée "La Ligue," LabEx DEVweCAN, Institut Convergence PLAsCAN, Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France; Netris Pharma, 69008 Lyon, France.
Benjamin DucarougeNetris Pharma, 69008 Lyon, France.
David GoldschneiderNetris Pharma, 69008 Lyon, France.
Xiaoyang SuRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Jason PitarresiDepartment of Medicine, Division of Hematology/Oncology, University of Massachusetts, Worcester, MA, USA.
Aram HezelDepartment of Medicine, Division of Medical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Subhajyoti DeRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Wade NarrowDepartment of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
Fady SolimanRutgers Robert Wood-Johnson Medical School, New Brunswick, NJ, USA.
Cory ShieldsWilmot Cancer Center, University of Rochester, Rochester, NY, USA.
Debora Barbosa Vendramini-CostaDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Orjola PrelaDepartment of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Lan WangDepartment of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Igor AstsaturovDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Patrick MehlenApoptosis, Cancer and Development Laboratory - Equipe labellisée "La Ligue," LabEx DEVweCAN, Institut Convergence PLAsCAN, Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France; Netris Pharma, 69008 Lyon, France.
Darren R CarpizoDepartment of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Wilmot Cancer Center, University of Rochester, Rochester, NY, USA. Electronic address: darren_carpizo@urmc.rochester.edu.
University of Rochester · USFox Chase Cancer Center · USCentre Léon Bérard · FRNetris Pharma (France) · FRRutgers Cancer Institute · USCentre de Recherche en Cancérologie de Lyon · FRInserm · FRJohnson University · USRutgers, The State University of New Jersey · USUniversity of Massachusetts Chan Medical School · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Dietmar J Kappes · 1985 to 2026
$138.8M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Synergistic targeting of cholesterol metabolism and EGFR signaling in cancerR01CA188430 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ASTSATUROV, IGOR · 2014 to 2018
$1.9M
Computational approaches for identifying epigenomic contexts of somatic mutationsR01GM129066 · NIGMS · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI DE, SUBHAJYOTI · 2019 to 2023
$1.7M
Computational genomic analysis of genomic variations in human tissuesR35GM149224 · NIGMS · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Subhajyoti De · 2023 to 2026
$1.4M
Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer StrategyK22CA160725 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ASTSATUROV, IGOR · 2011 to 2013
$592k
Oncogenic Synapses: cell-cell contacts enabling trogocytic-based metabolic interactions between pancreatic cancer and fibroblastic stromal cellsR21CA231252 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ASTSATUROV, IGOR, CUKIERMAN, EDNA · 2019 to 2020
$437k
Regulation of EGFR by SC4MOL- and NSDHL-Dependent TraffickingR21CA164205 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ASTSATUROV, IGOR · 2012 to 2013
$413k
NCI NIH HHS K22 CA160725NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA188430NCI NIH HHS R21 CA164205NCI NIH HHS R21 CA231252NIGMS NIH HHS R01 GM129066
6 · The paper itself

Abstract

The biology of metastatic pancreatic ductal adenocarcinoma (PDAC) is distinct from that of the primary tumor due to changes in cell plasticity governed by a distinct transcriptome. Therapeutic strategies that target this distinct biology are needed. We detect an upregulation of the neuronal axon guidance molecule Netrin-1 in PDAC liver metastases that signals through its dependence receptor (DR), uncoordinated-5b (Unc5b), to facilitate metastasis in vitro and in vivo. The mechanism of Netrin-1 induction involves a feedforward loop whereby Netrin-1 on the surface of PDAC-secreted extracellular vesicles prepares the metastatic niche by inducing hepatic stellate cell activation and retinoic acid secretion that in turn upregulates Netrin-1 in disseminated tumor cells via RAR/RXR and Elf3 signaling. While this mechanism promotes PDAC liver metastasis, it also identifies a therapeutic vulnerability, as it can be targeted using anti-Netrin-1 therapy to inhibit metastasis using the Unc5b DR cell death mechanism.

Indexed as

Carcinoma, Pancreatic DuctalLiver NeoplasmsPancreatic NeoplasmsCell Line, TumorDNA-Binding ProteinsHepatic Stellate CellsHumansNetrin-1Netrin ReceptorsProto-Oncogene Proteins c-etsRetinoidsTranscription FactorsDNA-Binding ProteinsELF3 protein, humanNetrin-1Netrin ReceptorsProto-Oncogene Proteins c-etsRetinoidsTranscription Factorsaxon guidanceCP: CancerElf3extracellular vesicleshepatic stellate cellsmetastasismetastatic nicheNetrin-1pancreatic cancerretinoic acidUnc5b

Identifiers

PMID37922311
PMCPMC12270551
OpenAlexW4388302402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.